NF-B and bone: The breaking point

New findings suggest that NF-B proteins regulate osteoclast differentiation and are potential therapeutic targets for treating osteoporosis (pages 1285—1289).

1. Baeuerle P.A. & Baltimore D. NF-B: ten years after. Cell 87, 13−20 (1996). | Article | PubMed  | ISI | ChemPort |
2. Lotsova V., Caamano J., Loy J., Lewin, A. & Bravo, R. Osteopetrosis in mice lacking NF-B1 and NF-B2. Nature Mad. 3, 1285−1289 (1997).
3. Grigoriadis, A.E. et al. c-Fos: A key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 266, 443−448 (1994). | PubMed  | ISI | ChemPort |
4. Manolagas, S.C., Bellido, T. & Jilka, R.L. New insights into the cellular, biochemical, and molecular basis of postmenopausal and senile osteoporosis: Roles of IL-6 and gp130. Int. J. Immunopharmacol. 17, 109−116 (1995). | Article | PubMed  | ISI | ChemPort |
5. Pacifici R. Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J. Bone Miner. Res. 11, 1043−1051 (1996). | PubMed  | ISI | ChemPort |
6. Ray A., Prefontaine K.E. & Ray, P. Downregulation of interleukin-6 gene by 17 beta-estradiol in the absence of high affinity DMA binding by the estrogen receptor. J. Biol. Chem. 269, 12940−12946 (1994). | PubMed  | ISI | ChemPort |
7. Stein, B. & Yang, M.X. Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-kappa B and C/EBP beta. Mol. Cell. Biol. 15, 4971−4979 (1995). | PubMed  | ISI | ChemPort |
8. Tondravi, M.M. et al. Osteopetrosis in mice lacking hematopoietic transcription factor PU.1. Nature 386, 81−84 (1997). | Article | PubMed  | ISI | ChemPort |
9. Stein, B. et al. Cross-coupling of the NF-kappa B p65 and Fos-Jun transcription factors produces potentiated biological function. EMBO J. 12, 3879−3891 (1993). | PubMed  | ISI | ChemPort |
10. Bassuk A.G. & Leiden J.M. A direct physical association between ETS and AP-1 transcription factors in normal human T Cells. Immunity 3, 223−237 (1995). | Article | PubMed  | ISI | ChemPort |

	Top

	Top